Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Azilsartan and Chlorthalidone: Azilsartan 40 mg and Chlorthalidone 12.5mg once daily for 12 weeks
Intervention2: Azilsartan and Chlorthalidone: Azilsartan 40 mg and Chlorthalidone 12.
Sponsors
AIIMSBhubaneswar
Dr Bikash Ranjan Meher
Eligibility
Inclusion criteria
Inclusion criteria: Hypertensive patients who had not achieved target BP level Willing to participate by giving a written informed consent.
Exclusion criteria
Exclusion criteria: Patients diagnosed with secondary hypertension Patients of hypertensive emergency and hypertensive urgency Presence of hyperkalaemia (potassium level >= 5.5 mEq) Pregnant and lactating women Patient history of allergic to Azilsartan, Telmisartan, and Chlorthalidone Any serious hepatic, cardiovascular, renal or pulmonary condition which may prevent participation in the study Any drug having adverse interaction with azilsartan, telmisartan, and chlorthalidone in term of safety and efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate and compare the change in blood pressure (systolic and diastolic) from baseline at 12 weeks in both the groupsTimepoint: At baseline and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ To evaluate and compare the proportion of patients who achieved blood pressure target ( 140/90 mmHg in all patients with hypertension without comorbidities and 130 mm Hg of systolic blood pressure in high risk patients) after 12 weeks of therapy â?¢ To evaluate and compare the changes in serum urea, serum creatinine, lipid profile after 12 weeks of therapy. â?¢ To compare treatment-emergent adverse events of the two treatment groups. â?¢ To compare the treatment satisfaction in both the groups after 12 weeks of therapy. Timepoint: At baseline and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Bikash Ranjan meher
All India Institute of Medical Sciences
Outcome results
None listed